105 related articles for article (PubMed ID: 26722028)
1. LPA Increases Tumor Growth and Bone Destruction Through Enhancement of Osteoclastogenic Cytokines.
Lindholm PF; Hwang YS
Anticancer Res; 2016 Jan; 36(1):61-70. PubMed ID: 26722028
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic acid activates the RhoA and NF-κB through Akt/IκBα signaling and promotes prostate cancer invasion and progression by enhancing functional invadopodia formation.
Hwang YS; Lee J; Zhang X; Lindholm PF
Tumour Biol; 2016 May; 37(5):6775-85. PubMed ID: 26662305
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.
Boucharaba A; Serre CM; Grès S; Saulnier-Blache JS; Bordet JC; Guglielmi J; Clézardin P; Peyruchaud O
J Clin Invest; 2004 Dec; 114(12):1714-25. PubMed ID: 15599396
[TBL] [Abstract][Full Text] [Related]
4. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases.
Boucharaba A; Serre CM; Guglielmi J; Bordet JC; Clézardin P; Peyruchaud O
Proc Natl Acad Sci U S A; 2006 Jun; 103(25):9643-8. PubMed ID: 16769891
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic acid: a potential mediator of osteoblast-osteoclast signaling in bone.
Sims SM; Panupinthu N; Lapierre DM; Pereverzev A; Dixon SJ
Biochim Biophys Acta; 2013 Jan; 1831(1):109-16. PubMed ID: 22892679
[TBL] [Abstract][Full Text] [Related]
6. Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism.
Schulze J; Albers J; Baranowsky A; Keller J; Spiro A; Streichert T; Zustin J; Amling M; Schinke T
Bone; 2010 Feb; 46(2):524-33. PubMed ID: 19796718
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.
Sudhan DR; Pampo C; Rice L; Siemann DW
Int J Cancer; 2016 Jun; 138(11):2665-77. PubMed ID: 26757413
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction responses to lysophosphatidic acid and sphingosine 1-phosphate in human prostate cancer cells.
Gibbs TC; Rubio MV; Zhang Z; Xie Y; Kipp KR; Meier KE
Prostate; 2009 Oct; 69(14):1493-506. PubMed ID: 19536794
[TBL] [Abstract][Full Text] [Related]
9. Secretion of IL-6 and IL-8 from lysophosphatidic acid-stimulated oral squamous cell carcinoma promotes osteoclastogenesis and bone resorption.
Hwang YS; Lee SK; Park KK; Chung WY
Oral Oncol; 2012 Jan; 48(1):40-8. PubMed ID: 21925926
[TBL] [Abstract][Full Text] [Related]
10. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.
Lu Y; Cai Z; Xiao G; Keller ET; Mizokami A; Yao Z; Roodman GD; Zhang J
Cancer Res; 2007 Apr; 67(8):3646-53. PubMed ID: 17440076
[TBL] [Abstract][Full Text] [Related]
11. Lysophosphatidic acid-induced ADAM12 expression mediates human adipose tissue-derived mesenchymal stem cell-stimulated tumor growth.
Do EK; Kim YM; Heo SC; Kwon YW; Shin SH; Suh DS; Kim KH; Yoon MS; Kim JH
Int J Biochem Cell Biol; 2012 Nov; 44(11):2069-76. PubMed ID: 22903068
[TBL] [Abstract][Full Text] [Related]
12. p65-Dependent production of interleukin-1β by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts.
Schulze J; Weber K; Baranowsky A; Streichert T; Lange T; Spiro AS; Albers J; Seitz S; Zustin J; Amling M; Fehse B; Schinke T
Cancer Lett; 2012 Apr; 317(1):106-13. PubMed ID: 22108531
[TBL] [Abstract][Full Text] [Related]
13. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
14. Krüppel-like factor 4 mediates lysophosphatidic acid-stimulated migration and proliferation of PC3M prostate cancer cells.
Shin SH; Kwon YW; Heo SC; Jeong GO; Kim BR; Seo EJ; Kim JH
Exp Mol Med; 2014 Jul; 46(7):e104. PubMed ID: 24993134
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
16. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
17. Aromatic hydrocarbon receptor inhibits lysophosphatidic acid-induced vascular endothelial growth factor-A expression in PC-3 prostate cancer cells.
Wu PY; Lin YC; Lan SY; Huang YL; Lee H
Biochem Biophys Res Commun; 2013 Aug; 437(3):440-5. PubMed ID: 23831623
[TBL] [Abstract][Full Text] [Related]
18. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.
van der Horst G; van den Hoogen C; Buijs JT; Cheung H; Bloys H; Pelger RC; Lorenzon G; Heckmann B; Feyen J; Pujuguet P; Blanque R; Clément-Lacroix P; van der Pluijm G
Neoplasia; 2011 Jun; 13(6):516-25. PubMed ID: 21677875
[TBL] [Abstract][Full Text] [Related]
19. Bone-metastatic prostate carcinoma favors mesenchymal stem cell differentiation toward osteoblasts and reduces their osteoclastogenic potential.
Fritz V; Brondello JM; Gordeladze JO; Reseland JE; Bony C; Yssel H; Noël D; Jorgensen C
J Cell Biochem; 2011 Nov; 112(11):3234-45. PubMed ID: 22009438
[TBL] [Abstract][Full Text] [Related]
20. Lysophosphatidic acid stimulates osteoclast fusion through OC-STAMP and P2X7 receptor signaling.
Hwang YS; Ma GT; Park KK; Chung WY
J Bone Miner Metab; 2014 Mar; 32(2):110-22. PubMed ID: 23624721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
